HK Stock Market Move | PEGBIO CO-B(02565) rose by over 6%, Paidacon's first batch of commercial prescriptions launched nationwide, receiving a second tranche of equity funding of about HK$49 million.

PEGBIO CO-B(02565) rose more than 6%, and as of the time of writing, it has risen by 6.1% to 7.48 Hong Kong dollars, with a turnover of 30.1567 million Hong Kong dollars. On the news front, on July 22, Pegbio announced that Padacan has gradually issued the first batch of commercial prescriptions in multiple medical institutions nationwide, including Peking University People's Hospital and Xiangya Second Hospital of Central South University, and has achieved the landing of the first batch of prescriptions through online medical service channels, officially entering the clinical application and patient use stage. With the issuance of the first batch of commercial prescriptions nationwide, the company has reached the payment condition for the second equity payment stipulated in the commercial cooperation agreement with Tengrui Pharmaceuticals, amounting to approximately 49 million Hong Kong dollars. Together with the first installment of approximately 61 million Hong Kong dollars in equity payment received earlier, Pegbio has now received and triggered a total of approximately 110 million Hong Kong dollars in equity payments.